Loading
Life sciences · Journal article
Pathogens · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Melioidosis, caused by Burkholderia pseudomallei, is an emerging infectious disease with significant public health implications, historically considered endemic to Southeast Asia and Northern Australia. However, growing evidence highlights its underdiagnosed and underreported status in Brazil, where its true burden remains poorly characterized due to a lack of routine surveillance. This review explores the etiological agent, epidemiology, environmental determinants, clinical manifestations, diagnosis, treatment, and public health impact of melioidosis in Brazil. Reported cases show a strong concentration in the Northeast region, with sporadic cases in the Central-West, Southeast, and North, suggesting a wider distribution than previously recognized. Clinical presentations range from localized cutaneous lesions to fulminant septicemia. The disease is frequently misdiagnosed as tuberculosis, leptospirosis, or other bacterial infections due to non-specific signs and limited laboratory capacity. As climatic changes may lead to bacterial persistence, melioidosis has established itself as an emerging disease that has been expanding geographically in Brazil, requiring improved surveillance, diagnostic capacity, and clinician awareness, along with stronger laboratory infrastructure and access to appropriate antimicrobial therapy.